title: [Clinical evaluation of the combination of carumonam and cefotiam in the treatment of complicated urinary tract infection].
abstract: The combination of carumonam (CRMN) and cefotiam (CTM), expected to have a broader spectrum of coverage in connection with urinary tract infections, was evaluated for its effectiveness and safety at the Department of Urology, Osaka University Hospital and 17 affiliated hospitals. CRMN and CTM were given together to 109 patients with complicated urinary tract infections (UTI), of whom 65 cases satisfied the "Criteria of UTI Committee for the Evaluation of Drug Efficacy in the UTI (3rd Ed.)", which was modified by adopting the midstream urine data for women. CRMN and CTM were administered by drip or one-shot infusion at a total daily dose of 4 g (equally mixed 1 g plus 1 g each, twice a day) for 5 consecutive days or longer. The overall clinical efficacy rate in the 65 cases of complicated UTI was 72%, estimated by the criteria cited above. The efficacy rate according to the infection type groupings was 72% for the 29 patients in the 1st group, 100% for the 1 patient in the 2nd group, 100% for the 7 patients in the 3rd group, 83% for the 6 patients in the 4th group, 50% for the 14 patients in the 5th group and 75% for the 8 patients in the 6th group. The disappearance rate of both urinary Gram positive cocci and Gram negative bacilli was 83.3%. Fifteen strains appeared after the treatment, only 4 of which were Gram positive cocci. Among the 109 patients treated with CRMN+CTM, no subjective side effects were recorded and the abnormalized laboratory findings observed were: eosinophilia in one patient, increases in both GPT and GOT in one patient, and lowered creatinine clearance in one patient. With a broader spectrum and safe regimen, the combination of CRMN/CTM is recommended as the first choice against complicated UTI.
authors.affiliation: Department of Urology, Osaka University Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Sonoda
authors.forename: E
authors.initials: E
authors.lastname: Nakano
authors.forename: T
authors.initials: T
authors.lastname: Seguchi
authors.forename: H
authors.initials: H
authors.lastname: Yano
authors.forename: H
authors.initials: H
authors.lastname: Kuroda
authors.forename: Y
authors.initials: Y
authors.lastname: Ihara
authors.forename: T
authors.initials: T
authors.lastname: Kishimoto
authors.forename: H
authors.initials: H
authors.lastname: Takatera
authors.forename: S
authors.initials: S
authors.lastname: Mizutani
authors.forename: N
authors.initials: N
authors.lastname: Iwao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001398:Aztreonam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015310:Cefotiam / Q000008:administration & dosage* / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: C044145:carumonam; D015310:Cefotiam; D001398:Aztreonam